Premium
ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer
Author(s) -
Gerber DE,
Oxnard GR,
Govindan R
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.91
Subject(s) - lung cancer , anaplastic lymphoma kinase , druggability , cancer , epidermal growth factor receptor , medicine , oncology , identification (biology) , stage (stratigraphy) , cancer research , biology , gene , genetics , botany , malignant pleural effusion , paleontology
The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute–sponsored initiative to address these questions in earlier‐stage disease.